JP2018507889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507889A5 JP2018507889A5 JP2017547514A JP2017547514A JP2018507889A5 JP 2018507889 A5 JP2018507889 A5 JP 2018507889A5 JP 2017547514 A JP2017547514 A JP 2017547514A JP 2017547514 A JP2017547514 A JP 2017547514A JP 2018507889 A5 JP2018507889 A5 JP 2018507889A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- cells
- pancreatic endocrine
- use according
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 13
- 230000009996 pancreatic endocrine effect Effects 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 7
- 239000002243 precursor Substances 0.000 claims 7
- 208000008589 Obesity Diseases 0.000 claims 6
- 239000003472 antidiabetic agent Substances 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 229940125708 antidiabetic agent Drugs 0.000 claims 5
- 230000002641 glycemic effect Effects 0.000 claims 5
- 150000003384 small molecules Chemical class 0.000 claims 5
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 4
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 claims 4
- 101710103228 Sodium/glucose cotransporter 2 Proteins 0.000 claims 4
- 210000003890 endocrine cell Anatomy 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 4
- 208000002705 Glucose Intolerance Diseases 0.000 claims 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 229960004034 sitagliptin Drugs 0.000 claims 3
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 2
- 229940123208 Biguanide Drugs 0.000 claims 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims 2
- 229940100389 Sulfonylurea Drugs 0.000 claims 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims 2
- 229960002632 acarbose Drugs 0.000 claims 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 2
- 229920000080 bile acid sequestrant Polymers 0.000 claims 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 2
- 229960004580 glibenclamide Drugs 0.000 claims 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims 2
- 229960004346 glimepiride Drugs 0.000 claims 2
- 229960001381 glipizide Drugs 0.000 claims 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960002397 linagliptin Drugs 0.000 claims 2
- 229950004994 meglitinide Drugs 0.000 claims 2
- 229960003105 metformin Drugs 0.000 claims 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 2
- 229960000698 nateglinide Drugs 0.000 claims 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 2
- 229960005095 pioglitazone Drugs 0.000 claims 2
- 229960002354 repaglinide Drugs 0.000 claims 2
- 229960004586 rosiglitazone Drugs 0.000 claims 2
- 229960004937 saxagliptin Drugs 0.000 claims 2
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 2
- 108010033693 saxagliptin Proteins 0.000 claims 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 2
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 229960001713 canagliflozin Drugs 0.000 claims 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940035732 metformin and rosiglitazone Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000003577 pancreatic endocrine progenitor Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562131540P | 2015-03-11 | 2015-03-11 | |
| US62/131,540 | 2015-03-11 | ||
| PCT/CA2016/000072 WO2016141460A1 (en) | 2015-03-11 | 2016-03-11 | Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507889A JP2018507889A (ja) | 2018-03-22 |
| JP2018507889A5 true JP2018507889A5 (https=) | 2019-04-18 |
| JP6847044B2 JP6847044B2 (ja) | 2021-03-24 |
Family
ID=56879832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547514A Active JP6847044B2 (ja) | 2015-03-11 | 2016-03-11 | 肥満及び２型糖尿病（ｔ２ｄ）の治療のための膵内分泌前駆細胞療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10772917B2 (https=) |
| EP (1) | EP3268016B1 (https=) |
| JP (1) | JP6847044B2 (https=) |
| CN (1) | CN107530379A (https=) |
| AU (1) | AU2016228894B2 (https=) |
| CA (1) | CA2979293C (https=) |
| WO (1) | WO2016141460A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11951136B2 (en) | 2017-12-12 | 2024-04-09 | The Regents Of The University Of California | Preservation of pancreatic islet grafts in the extrahepatic space |
| WO2019142883A1 (ja) | 2018-01-18 | 2019-07-25 | 第一三共株式会社 | ジヒドロインドリジノン誘導体 |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| AU2020279820B2 (en) | 2019-05-22 | 2026-04-23 | The Cleveland Clinic Foundation | Generating dorsal foregut, and anterior domain, endoderm cells |
| CN110585242A (zh) * | 2019-10-15 | 2019-12-20 | 南通大学 | 多系分化持续应激细胞的应用、治疗糖尿病的药物及其制备方法 |
| CN111411072B (zh) * | 2020-03-09 | 2022-10-11 | 同济大学 | SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用 |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6703017B1 (en) * | 1994-04-28 | 2004-03-09 | Ixion Biotechnology, Inc. | Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| KR20090115984A (ko) * | 2001-11-09 | 2009-11-10 | 아르테셀 사이언스, 인크. | 지방 조직에서 유래된 기질세포의 내분비 췌장 분화 및 이의 용도 |
| IL165242A0 (en) * | 2002-05-24 | 2005-12-18 | Waratah Pharmaceuticals Inc | Treatment for diabetes |
| JP2005537803A (ja) * | 2002-09-06 | 2005-12-15 | アムサイト インコーポレーティッド | Ｃｄ５６陽性ヒト成体膵臓内分泌前駆細胞 |
| WO2005001080A2 (en) | 2003-06-27 | 2005-01-06 | Ethicon, Incorporated | Postpartum-derived cells for use in treatment of disease of the heart and circulatory system |
| CN1589904A (zh) * | 2003-09-01 | 2005-03-09 | 北京大学 | 造血干细胞动员剂制备治疗糖尿病药物的用途 |
| JP2006149380A (ja) * | 2004-10-27 | 2006-06-15 | Kobe Univ | 遺伝子改変動物の新規用途 |
| AU2006202209B2 (en) | 2005-05-27 | 2011-04-14 | Lifescan, Inc. | Amniotic fluid derived cells |
| CN102016582A (zh) * | 2006-10-31 | 2011-04-13 | 国家干细胞控股公司 | 鉴别、分离和利用来自成人胰腺的内分泌祖细胞的方法 |
| TWI609702B (zh) * | 2006-11-09 | 2018-01-01 | 歐瑞根治療有限公司 | 層狀醫藥調配物 |
| CA2954431C (en) | 2007-11-27 | 2021-08-24 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic cells |
| CA2723820A1 (en) * | 2008-05-09 | 2009-11-12 | Vistagen Therapeutics, Inc. | Pancreatic endocrine progenitor cells derived from pluripotent stem cells |
| AU2010212823B2 (en) * | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| PL2494035T3 (pl) | 2009-10-29 | 2018-07-31 | Janssen Biotech, Inc. | Pluripotencjalne komórki macierzyste |
| WO2011160066A1 (en) * | 2010-06-17 | 2011-12-22 | Regents Of The University Of Minnesota | Production of insulin producing cells |
| KR20190027969A (ko) * | 2010-08-12 | 2019-03-15 | 얀센 바이오테크 인코포레이티드 | 췌장 내분비 전구 세포를 이용한 당뇨병의 치료 |
| US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
-
2016
- 2016-03-11 US US15/556,907 patent/US10772917B2/en active Active
- 2016-03-11 WO PCT/CA2016/000072 patent/WO2016141460A1/en not_active Ceased
- 2016-03-11 EP EP16760957.7A patent/EP3268016B1/en active Active
- 2016-03-11 AU AU2016228894A patent/AU2016228894B2/en active Active
- 2016-03-11 CN CN201680024439.5A patent/CN107530379A/zh active Pending
- 2016-03-11 JP JP2017547514A patent/JP6847044B2/ja active Active
- 2016-03-11 CA CA2979293A patent/CA2979293C/en active Active
-
2020
- 2020-08-03 US US16/983,810 patent/US20210015872A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507889A5 (https=) | ||
| PE20120017A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv, opcionalmente, un agente antidiabetico adicional, y sus usos | |
| JP2017515908A5 (https=) | ||
| JP2016501841A5 (https=) | ||
| JP2017160212A5 (https=) | ||
| NZ598170A (en) | Pharmaceutical compositions comprising bi-1356 and metformin | |
| RU2014121260A (ru) | Фармацевтические композиции | |
| JP2011241213A5 (https=) | ||
| HRP20181026T1 (hr) | Dugodjelujuće formulacije inzulina | |
| AR084698A1 (es) | Composiciones de liberacion controlada con reducido efecto de alimentos, reducida interaccion entre farmaco y los alimentos | |
| EP1841448A2 (en) | Pharmaceutical compositions and methods for restoring beta-cell mass and function | |
| CL2012001337A1 (es) | Uso de una combinacion farmacéutica que comprende un inhibidor de dpp-4 y opcionalmente un segundo y/o un tercer agente diabético seleccionado entre biguanidas, tiazolidindionas, sulfonilureas, glinidas, inhibidores de alfa-glucosidasa, glp-1 e insulina, diferentes entre ellos, para el tratamiento de diabetes mellitus de tipo 2. | |
| JP2015044875A5 (https=) | ||
| JP2016512205A5 (https=) | ||
| WO2006096565A3 (en) | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions | |
| ECSP088353A (es) | Composiciones farmacéuticas que comprenden sustancias antidiabéticas combinadas para su uso en diabetes mellitus | |
| RU2012147449A (ru) | Способы использования диацереина в дополнительном лечении диабета | |
| CA3003319C (en) | Method of treating hyperglycemia | |
| Davis | Oral hypoglycaemic drugs for the treatment of type 2 diabetes mellitus | |
| WO2011128782A3 (en) | Compositions and methods for treating type ii diabetes and related disorders | |
| RU2007141058A (ru) | Новое применение агонистов печеночного рецептора х | |
| CA2750074A1 (en) | Use of cardiotrophin-1 for the treatment of metabolic diseases | |
| CO2023002829A2 (es) | Formulación compuesta para tratamiento de diabetes mellitus tipo 2 | |
| US20110052625A1 (en) | Compositions and methods for treating diabetes using lisofylline analogs and islet neogenesis associated peptide | |
| de Arellano et al. | Cost-Effectiveness Analysis of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn (Nph) In Patients With Type 1 Diabetes Mellitus In Spain |